Media stories about Nivalis Therapeutics (NASDAQ:ALPN) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nivalis Therapeutics earned a news sentiment score of 0.02 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.0633619590975 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

A number of analysts recently weighed in on ALPN shares. Zacks Investment Research raised shares of Nivalis Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Wednesday, April 19th. Cowen and Company reaffirmed a “hold” rating on shares of Nivalis Therapeutics in a research report on Wednesday, April 19th. ValuEngine cut shares of Nivalis Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Ladenburg Thalmann Financial Services started coverage on shares of Nivalis Therapeutics in a research report on Thursday, July 27th. They set a “buy” rating and a $17.00 price target for the company. Two analysts have rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $8.81.

Nivalis Therapeutics (NASDAQ ALPN) opened at 8.80 on Tuesday. Nivalis Therapeutics has a one year low of $8.00 and a one year high of $37.40. The firm has a 50-day moving average of $9.28 and a 200-day moving average of $9.83. The firm’s market cap is $11.79 million.

In other news, insider Value Fund L. P. Biotechnology bought 78,858 shares of the stock in a transaction that occurred on Friday, May 19th. The shares were acquired at an average cost of $2.30 per share, for a total transaction of $181,373.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Value Fund L. P. Biotechnology bought 17,806 shares of the stock in a transaction that occurred on Tuesday, June 20th. The stock was purchased at an average price of $2.25 per share, for a total transaction of $40,063.50. The disclosure for this purchase can be found here. Insiders purchased a total of 288,964 shares of company stock worth $660,495 over the last quarter. 3.00% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Nivalis Therapeutics (ALPN) Getting Somewhat Favorable Media Coverage, Study Shows” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/nivalis-therapeutics-alpn-getting-somewhat-favorable-media-coverage-study-shows/1488477.html.

About Nivalis Therapeutics

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.